Best Chromatography Podcasts (2025)

1
196: Monolithic Chromatography Innovations: Solving High-Capacity Purification for Gene Therapy Vectors with Alois Jungbauer - Part 2 25:04

Play Pause

8d ago25:04

25:04

What if solving tomorrow’s bioprocessing challenges meant questioning the very physics of chromatography and reimagining downstream processing from the ground up? For years, large biomolecules like viral vectors and exosomes have squeezed through the limitations of traditional chromatography, leaving scientists to wrestle with capacity trade-offs a…

1
Rediscovering Slalom Chromatography – A Forgotten Technique Reimagined 39:23

10d ago39:23

39:23

By Waters Corporation

1
198: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 2 21:57

1d ago21:57

21:57

What happens when the most complex molecules in biotech meet the organizational challenge of managing 300+ analytical scientists? The answer lies not just in the science, but in building systems that turn technical complexity into reliable delivery. In Part 2 of our deep dive with Amanda Hoertz, VP of Analytical and Formulation Sciences at KBI Biop…

1
197: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 1 25:58

3d ago25:58

25:58

What if the key to unlocking ADC manufacturing success lies in abandoning the platform mindset entirely? Antibody-drug conjugates represent biotech's most promising weapon against cancer: precision-targeted therapeutics that deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue. But beneath the clinical promise lies a manu…

1
195: Monolithic Chromatography Innovations: Solving High-Capacity Purification for Gene Therapy Vectors with Alois Jungbauer - Part 1 20:48

10d ago20:48

20:48

By David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist

1
194: Viral Vector CDMO Mastery: Singapore's Answer to Cell and Gene Therapy Supply Shortages with Lucas Chan - Part 2 19:18

15d ago19:18

19:18

What if the future of affordable, life-changing cell and gene therapies comes down to one critical yet often overlooked factor: manufacturing efficiency? In advanced therapy medicinal products (ATMPs), groundbreaking science abounds, but the path to the clinic is still strewn with bottlenecks, especially when it comes to cost, complexity, and safet…

1
193: Viral Vector CDMO Mastery: Singapore's Answer to Cell and Gene Therapy Supply Shortages with Lucas Chan - Part 1 29:11

17d ago29:11

29:11

Viral vectors are the backbone of cutting-edge cell and gene therapies, delivering life-altering treatments to patients with genetic diseases. But making these biological delivery vehicles is a high-wire act: unpredictable, complex, and fraught with hurdles that traditional biologics manufacturers have never faced. While the world races toward next…

1
192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan - Part 2 19:43

22d ago19:43

19:43

Is continuous manufacturing delivering the transformative results everyone promised, or are you being sold an expensive solution to the wrong problem? While industry headlines tout revolutionary productivity gains, the economic reality behind continuous bioprocessing tells a more nuanced story that every process engineer needs to understand before …

1
191: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan - Part 1 21:16

24d ago21:16

21:16

What if process intensification could transform your bioprocessing economics without the complexity most engineers fear? Getting 3x productivity gains and 30-150% titer increases once seemed reserved for Big Pharma's endless R&D budgets, but a strategic approach to technology selection is making these results achievable for companies of any size. I…

1
190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later) - Part 2 18:47

29d ago18:47

18:47

Still think you can "figure out CMC later"? Your competitors just implemented a systematic framework that cuts their IND timeline in half while you're still debating whether CMC matters. The founders who file INDs predictably aren't smarter than you. They just stopped gambling with ad-hoc CMC approaches and started executing proven systems. While y…

1
189: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later) - Part 1 16:04

1M ago16:04

16:04

Think you can crack the science first and worry about CMC when you "need it"? That's exactly how promising therapies die in regulatory limbo while patients keep waiting. Your breakthrough discovery means nothing if it's trapped in CMC chaos. While you're perfecting your molecular mechanism, competitors with inferior science but superior CMC strateg…

1
188: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême - Part 2 24:41

1M ago24:41

24:41

For too long, biotech innovators have viewed biological systems as inherently messy, unpredictable, and full of “black box” mysteries. But what if, armed with the latest digital tools, AI, and cross-disciplinary thinking, you could transform bioprocessing from a series of trial-and-error experiments to a streamlined, proactive design process? Carme…

1
Adopting AQbD Principles to Method Development 29:16

1M ago29:16

29:16

In Episode 9 of Chromatography Life, we sit down with Richard Verseput, a pioneer in QbD-driven analytical development, to explore how automation, risk assessment, and smart experimental design are revolutionizing chromatography. From cutting-edge tools like Fusion QbD to real-world strategies for building robust, adaptable methods, this episode is…

1
187: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême - Part 1 21:19

1M ago21:19

21:19

Almost every corner of modern medicine and sustainable food production today is facing a massive challenge: how do we outpace drug-resistant “superbugs” and create food for a growing population using fewer resources? The answer, it turns out, may come down to how well we understand and control the biomanufacturing processes underpinning these bioma…

1
186: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 2 17:33

1M ago17:33

17:33

Imagine unlocking a world where designing custom proteins is not only feasible - but faster, smarter, and more powerful than ever before, thanks to artificial intelligence. As the promise of programmable biology takes center stage, AI-driven protein engineering is rapidly moving from theoretical dream to industry standard. In this episode, David Br…

1
185: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 1 24:36

2M ago24:36

24:36

For decades, protein design has hinged on painstaking rounds of wet lab mutagenesis and trial-and-error, a process limited not by human ingenuity, but by time and complexity. Yet as the biotech field seeks faster, greener, and more effective solutions for therapeutics and industrial applications, the next leap might not come solely from the lab ben…

1
184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 2 19:21

2M ago19:21

19:21

What’s the secret to turning a cutting-edge scientific breakthrough into a commercial biotech success? For every inspiring lab discovery, countless prototypes stall before ever reaching the market. The barriers? Securing the right beta testers, outmanoeuvring industry giants, and building teams who understand not just the science, but the user expe…

1
183: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 1 24:54

2M ago24:54

24:54

Every year, cutting-edge biomedical technologies are left stranded in the lab, not for lack of innovation, but because they miss the crucial leap from technical performance to genuine industry adoption. The gap between scientific brilliance and commercial success is deceptively simple: deeply understanding and building for your customer’s real-worl…

1
182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin - Part 2 17:04

2M ago17:04

17:04

What if the secret to making continuous bioprocessing practical, sustainable, and far simpler has been shaking - literally - just beneath our feet? For years, the industry has grappled with the complexities of continuous manufacturing, with technologies like ATF (alternating tangential flow) steadily dominating the perfusion landscape. But what if …

1
181: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin - Part 1 25:45

2M ago25:45

25:45

What if one of biotech’s biggest production breakthroughs was hiding in plain sight? Not in a new gene or a wonder drug, but in the way we process and purify biologics. Perfusion technology, once dismissed as a pipedream in top biopharma boardrooms, is now quietly powering some of the industry’s most efficient and productive manufacturing platforms…

1
180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davis - Part 2 26:52

2M ago26:52

26:52

The promise of advanced cell therapies is undeniable, but as demand skyrockets, the challenges of taking a living drug from bench to bedside have never been greater. Each batch brings variability, each jurisdiction adds regulatory hurdles, and every strategic decision can determine whether a lifesaving therapy reaches patients or fizzles out behind…

1
Equilibration Injections Under the Microscope 27:35

2M ago27:35

27:35

Join host Neil Lander as he sits down with Peter Baker, President of Live Oak Quality Assurance and former FDA Investigator of the Year, to explore the complexities of equilibration injections in regulated laboratories. Peter shares his global regulatory experience, offering insights into data integrity, risk management, and how to avoid common com…

1
179: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies - Part 1 23:33

2M ago23:33

23:33

By David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist

1
178: Rethinking Cultivated Meat Production: Scale and Media Optimization Strategies Slashing Manufacturing Costs with Richard Alldread - Part 2 21:05

2M ago21:05

21:05

By David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist

1
177: Rethinking Cultivated Meat Production: Scale and Media Optimization Strategies Slashing Manufacturing Costs with Richard Alldread - Part 1 23:59

2M ago23:59

23:59

What if the secrets to feeding the planet - and democratizing access to future protein - were hiding in the core toolkit of biopharma? The worlds of biopharmaceuticals and cultured food may seem galaxies apart, but at their heart, both rely on remarkably similar technology: media, bioreactors, and cell processing. Yet, as demand grows for sustainab…

1
176: How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine - Part 2 14:29

3M ago14:29

14:29

What if the missing link to resilient European bioproduction is not just another breakthrough technology, but the ability to continuously learn, adapt, and collaborate? In a rapidly shifting biotech landscape, innovation isn’t only driven by technical prowess. Behind every robust production process and every cutting-edge therapy, there’s a team emp…

1
175: How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine - Part 1 19:40

3M ago19:40

19:40

What if the road to bioproduction mastery started not in the lab, but with how you train your people? Traditional biotech education often ends at theory, leaving graduates unprepared for the fast-paced world of manufacturing. But what if the key to faster, safer, and more scalable bioprocessing is digital immersion, letting scientists train in a vi…

1
174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey - Part 2 20:33

3M ago20:33

20:33

How do you transform hybrid model digital twins from promising lab concepts into commercial bioprocessing game-changers that actually deliver ROI? As biotech companies race to implement Industry 4.0 technologies, the critical challenge isn't just developing sophisticated hybrid models - it's deploying them strategically to create user-friendly, cos…

1
173: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey - Part 1 22:48

3M ago22:48

22:48

Are you struggling to bridge the gap between lab-scale models and commercial bioprocessing reality? For many biotech innovators, the promise of digital twins meets harsh industrial constraints - where hybrid models that excel in controlled lab environments must prove themselves in the complexity of large-scale manufacturing. This week on the Smart …

1
172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2 19:43

3M ago19:43

19:43

Downstream processing remains one of the most complex and critical steps in biomanufacturing, especially as new therapeutic modalities like cell and gene therapies push current technologies to their limits. The industry faces ongoing pressure to innovate, reduce costs, and improve efficiency, while still ensuring robust and reliable results. In thi…

1
171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1 20:35

3M ago20:35

20:35

For decades, chromatographic purification has made use of bead-based diffusion - a reliable but limiting approach, especially as new modalities like gene therapies, mRNA, and viruses push the boundaries of what’s possible. But what if the future of downstream processing lies not in incremental improvement, but in a dramatic reimagining - from slow …

1
170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2 24:24

3M ago24:24

24:24

For years, disease diagnosis and treatment have focused on a few biomarkers, overlooking thousands of vital biological signals. Despite biotech advances, most therapies are still based on limited data, missing countless breakthroughs. Multiomics changes that. By analyzing tens of thousands of proteins, metabolites, and lipids, it reveals hidden ins…

1
Tools to Support Enhanced Method Development 10:30

3M ago10:30

10:30

Join host Neil Lander as he sits down with Margaret Maziarz, Principal Scientist at Waters Corporation, to discuss the latest tools and strategic approaches to optimizing method development. Margaret guides us through the advantages to various types of instrumentation, the importance of selecting the right column chemistry, and the powerful capabil…

1
169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1 27:17

3M ago27:17

27:17

What if the secret to truly personalized precision medicine lies not in your genetic code, but in your zip code? For years, biotech has focused on genomics to explain disease and drug response, but DNA only accounts for a fraction of the story. The real breakthrough? Multi-omics: the large-scale analysis of proteins, metabolites, and lipids, powere…

1
168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2 26:35

4M ago26:35

26:35

The promise of generative AI in pharma and biotech is huge, but it's also fraught with complexity, especially when it comes to integrating these systems into highly regulated environments. From monitoring evolving guidelines to balancing operational efficiency and data integrity, the journey from hype to real-world impact is filled with both opport…

1
167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1 15:14

4M ago15:14

15:14

Ever feel like you’re drowning in an ocean of constantly shifting regulatory guidelines? The world of biotech is a whirlwind of evolving standards, making compliance not just a headache, but sometimes the stumbling block between life-changing therapies and the patients who need them. But what if artificial intelligence could turn regulatory chaos i…

1
5 in 30 (Reunion Island psychotropic cocktail, GHB: Doctors vs Toxicologists, New-fangled fragmentation and more) 33:16

4M ago33:16

33:16

We look at 5 recent publications in the field of toxicology. Dietzen, Dennis J., and Connor J. Blair. "Precision Chemotherapy: Optimizing Calibration for Rapid Determination of Blood Methotrexate by Tandem Mass Spectrometry±Liquid Chromatography." Rapid Communications in Mass Spectrometry 39.14 (2025): e10053. Skjelland, D., Jørgenrud, B. M., Gunde…

1
166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 2 17:02

4M ago17:02

17:02

Have you ever presented a major scientific breakthrough, only to be met with blank stares and distracted executives? You're not alone. In this episode, David Brühlmann shares how he went from drowning in data to winning an innovation contest, not through better tech, but through the power of scientific storytelling. Many scientists default to metho…

1
165: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 1 18:44

4M ago18:44

18:44

Have you ever poured months of research into a brilliant innovation, only to watch executives’ eyes glaze over during your presentation? You’re not alone. In this episode, host David Brühlmann describes a familiar frustration: scientists are trained to perfect data, not to sell ideas. But in today’s fast-paced biotech landscape, even the most groun…

1
Advancements and Challenges in GLP-1 Peptide Drugs 23:58

4M ago23:58

23:58

This episode of Chromatography Life takes a closer look at the evolving landscape of synthetic peptide drugs - one of the most compelling frontiers in biopharmaceutical analysis. Joining us is Matt Lauber, Senior Director at Waters and a recognized authority in bioanalysis and drug product characterization, who shares both his personal and professi…

1
164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 2 21:01

4M ago21:01

21:01

From lab curiosity to commercial reality. Here's what happens when moss meets the brutal economics of bioprocessing. In Part 1, you've heard the science behind moss-based protein production. Now comes the real test: Can it survive the gauntlet of regulatory scrutiny, cost pressures, and manufacturing scale-up that crushes most biotech innovations? …

1
163: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 1 25:32

4M ago25:32

25:32

What if the future of "impossible" protein therapeutics is hiding in your backyard? For decades, CHO cells have ruled the biotech kingdom as the undisputed champions of complex protein production. But here's the uncomfortable truth: countless breakthrough therapies are gathering dust on laboratory shelves—not because the science failed, but because…

1
162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2 15:35

4M ago15:35

15:35

The world of cell therapy is changing rapidly, with revolutionary advancements in cryopreservation and bioprocessing protocols leading the way. In a recent episode of the Smart Biotech Scientist Podcast, host David Brühlmann sat down with Jeffrey Allen, Chairman and CEO of Evia Bio, to dive deep into the “how” of implementing cutting-edge technique…

1
161: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 1 27:36

4M ago27:36

27:36

If you’ve ever worked in a cell therapy lab or handled biologics, you’ve probably experienced the pitfalls of cryopreservation. We’ve all mourned the loss of precious samples after a freeze-thaw cycle gone wrong or watched viability figures plummet, wondering where it all went awry. In this episode of The Smart Biotech Scientist Podcast, Jeffrey Al…

1
NPS Update - June 2025 40:26

4M ago40:26

40:26

WIN A TOXPOD MUG! Listen to the episode and email [email protected] the name of the EUDA's 1000th drug and we'll send one lucky listener a coveted Toxpod mug! Keeping up to date with New Psychoactive Substances is hard! We've assembled a crack team of international experts to help us do just that: Michael Evans-Brown, EUDA Jared Brown, UNODC Alex Kr…

1
160: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 2 20:03

4M ago20:03

20:03

In this concluding episode of our deep dive into miniaturized perfusion systems, we tackle the most challenging aspect: implementing meaningful process analytical technology (PAT) at microscale while keeping costs realistic for high-throughput applications. Tom Valentin, group leader at CSEM for Automated Sample Handling, continues sharing CSEM's p…

1
159: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 1 24:14

5M ago24:14

24:14

In bioprocess development, the ability to rapidly screen conditions and predict scale-up performance can mean the difference between a successful therapy launch and costly delays. Today's Smart Biotech Scientist episode features Tom Valentin from CSEM, who's pioneering revolutionary approaches to miniaturized perfusion systems that could transform …

1
158: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 2 16:25

5M ago16:25

16:25

In this concluding episode of our series on revolutionary endotoxin detection, we continue our conversation with Anika Hoffmann about transitioning from theory to practice in the quest for more reliable, sustainable testing methods. Anika is a postdoctoral researcher in analytical chemistry at HES-SO Valais-Wallis, Switzerland. Having established w…

1
157: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 1 22:38

5M ago22:38

22:38

In biopharmaceutical manufacturing, endotoxins represent a silent but deadly threat – bacterial fragments capable of triggering severe immune responses at picogram levels, potentially leading to septic shock, organ failure, or even death in patients. In this eye-opening first episode, we speak with Anika Hoffmann, a postdoctoral researcher in analy…

1
156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook 27:29

5M ago27:29

27:29

The world of biologics manufacturing is undergoing a major transformation. Once dominated by traditional batch processes, the industry is now experiencing a marked shift toward continuous bioprocessing. But as companies contemplate this transition, two questions dominate strategic discussions: Will regulators accept continuous manufacturing? And, p…